Patient treatment preferences in localized prostate carcinoma: The influence of emotion, misconception, and anecdote
- PMID: 16802287
- DOI: 10.1002/cncr.22033
Patient treatment preferences in localized prostate carcinoma: The influence of emotion, misconception, and anecdote
Abstract
Background: Multiple therapeutic options exist for localized prostate carcinoma, without conclusive evidence to guide the choice of treatment. Thus, treatment should reflect trade-offs between the probability of curing disease and the desire to avoid treatment-associated side effects. Factors that actually influence patient treatment preferences are poorly understood.
Methods: We reviewed medical records and carried out in-depth, semistructured interviews of 20 men with newly-diagnosed, clinically-localized prostate carcinoma in a Veterans Affairs Hospital following their first consultations with urologists and before treatments were initiated. Six to eight months after treatment, we carried out follow-up interviews. Interviews explored beliefs and attitudes about prostate cancer and treatment options, emotional reactions to the diagnosis, treatment preferences, information sources, and perceptions of interactions with urologists.
Results: Patient treatment preferences were not based on careful assessments of numerical risks for various clinical outcomes. Instead, feelings of fear and uncertainty contributed to a desire for rapid treatment, and specific preferences were profoundly influenced by misconceptions, especially about prostatectomy, and by anecdotes about the experiences of others with cancer. Few patients wanted to seek second opinions. Most patients received treatments that matched their initial preferences. Afterwards, they justified their choices in terms of the same misconceptions and anecdotal influences invoked during treatment deliberation.
Conclusions: For men with localized prostate carcinoma, the treatment decision-making process would benefit from interventions that moderate feelings of fear and a desire for rapid treatment, dispel common and powerful misconceptions about prostate cancer and its therapies, and help patients avoid over-reliance on anecdotes.
Copyright 2006 American Cancer Society.
Similar articles
-
Treatment decision-making strategies and influences in patients with localized prostate carcinoma.Cancer. 2005 Oct 1;104(7):1381-90. doi: 10.1002/cncr.21330. Cancer. 2005. PMID: 16080181
-
Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study.Cancer. 2003 Apr 1;97(7):1653-62. doi: 10.1002/cncr.11233. Cancer. 2003. PMID: 12655522
-
A prospective study of the use of alternative therapies by men with localized prostate cancer.Patient Educ Couns. 2004 Oct;55(1):70-7. doi: 10.1016/j.pec.2003.07.007. Patient Educ Couns. 2004. PMID: 15476992
-
Current decision-making in prostate cancer therapy.Curr Opin Urol. 2008 May;18(3):275-8. doi: 10.1097/MOU.0b013e3282fba5f2. Curr Opin Urol. 2008. PMID: 18382237 Review.
-
Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.J Urol. 2007 Feb;177(2):540-5. doi: 10.1016/j.juro.2006.10.097. J Urol. 2007. PMID: 17222629 Review.
Cited by
-
Reproductive Results in Cancer Survivors after Fertility Sparing Management: The Need for the Standardization of Definitions.Cancers (Basel). 2023 Jul 11;15(14):3569. doi: 10.3390/cancers15143569. Cancers (Basel). 2023. PMID: 37509232 Free PMC article. Review.
-
How do cancer patients refuse treatment? A grounded theory study.BMC Palliat Care. 2023 Feb 7;22(1):10. doi: 10.1186/s12904-023-01132-5. BMC Palliat Care. 2023. PMID: 36750817 Free PMC article.
-
Concordance between influential adverse treatment outcomes and localized prostate cancer treatment decisions.BMC Med Inform Decis Mak. 2022 Aug 24;22(1):223. doi: 10.1186/s12911-022-01972-w. BMC Med Inform Decis Mak. 2022. PMID: 36002847 Free PMC article.
-
Patient Decision-Making Factors in Aggressive Treatment of Low-Risk Prostate Cancer.JNCI Cancer Spectr. 2022 Jan 5;6(1):pkac003. doi: 10.1093/jncics/pkac003. JNCI Cancer Spectr. 2022. PMID: 35699497 Free PMC article.
-
Decisional Conflict is Associated with Treatment Modality and not Disease Knowledge in South African Men with Prostate Cancer: Baseline Results from a Longitudinal Prospective Observational Study.Cancer Control. 2022 Jan-Dec;29:10732748221082791. doi: 10.1177/10732748221082791. Cancer Control. 2022. PMID: 35442835 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
